Targeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations

Marissa J. Schafer, Andrew J. Haak, Daniel J. Tschumperlin, Nathan K. LeBrasseur

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Purpose of the Review: Senescent cells have the capacity to both effect and limit fibrosis. Senotherapeutics target senescent cells to improve aging conditions. Here, we review the contexts in which senescent cells mediate wound healing and fibrotic pathology and the potential utility of senotherapeutic drugs for treatment of fibrotic disease. Recent Findings: Multi-action and temporal considerations influence deleterious versus beneficial actions of senescent cells. Acutely generated senescent cells can limit proliferation, and the senescence-associated secretory phenotype (SASP) contains factors that can facilitate tissue repair. Long-lived senescent cells that evade clearance or are generated outside of programmed remodeling can deplete the progenitor pool to exhaust regenerative capacity and through the SASP, stimulate continual activation, leading to disorganized tissue architecture, fibrotic damage, sterile inflammation, and induction of bystander senescence. Summary: Senescent cells contribute to fibrotic pathogenesis in multiple tissues, including the liver, kidney, and lung. Senotherapeutics may be a viable strategy for treatment of a range of fibrotic conditions.

Original languageEnglish (US)
Article number3
JournalCurrent rheumatology reports
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2018

    Fingerprint

Keywords

  • Aging
  • Cellular senescence
  • Fibrosis
  • Inflammation
  • Senolytics
  • Senomorphics
  • Senotherapeutics
  • Wound healing

ASJC Scopus subject areas

  • Rheumatology

Cite this